Suppr超能文献

微生物组在慢性阻塞性肺疾病中的意义。

Significance of the microbiome in chronic obstructive pulmonary disease.

机构信息

1 Division of Pulmonary and Critical Care, University of Michigan Health System, Ann Arbor, Michigan.

出版信息

Ann Am Thorac Soc. 2013 Dec;10 Suppl(Suppl):S170-9. doi: 10.1513/AnnalsATS.201306-204AW.

Abstract

Chronic obstructive pulmonary disease (COPD) is one of few chronic disorders with rising mortality and morbidity. It is a highly prevalent disorder, characterized by highly heterogeneous clinical symptoms, health status, and disease progression. COPD is also characterized by an inflammatory/immune response that persists despite smoking cessation and varies by the patient population, method of assessment, and timing of measurement. Bacterial colonization or infection is ubiquitous in patients with COPD and, until recently, has been predominantly assessed using culture-based methodologies. This colonization has been believed to be biologically relevant. It has been estimated that more than 70% of the bacterial species on body surfaces cannot be cultured by standard techniques. As such, advanced culture-independent techniques have been developed that target bacterial genes, such as the 16S ribosomal RNA gene, that function as molecular chronometers. Application of these techniques in patients with COPD has suggested microbial diversity that varies by age, disease severity, and medication use. All of these data provide unique and rapidly evolving insight into the potential role of the respiratory microbiome in disease genesis and expression.

摘要

慢性阻塞性肺疾病(COPD)是少数几种死亡率和发病率不断上升的慢性疾病之一。它是一种高度流行的疾病,其临床症状、健康状况和疾病进展高度异质。COPD 还具有炎症/免疫反应的特征,尽管已经戒烟,但这种反应仍然存在,而且因患者人群、评估方法和测量时间的不同而有所不同。细菌定植或感染在 COPD 患者中普遍存在,直到最近,主要还是通过基于培养的方法来评估。这种定植被认为具有生物学相关性。据估计,超过 70%的体表面细菌物种不能用标准技术培养。因此,已经开发了先进的非培养依赖性技术,这些技术针对细菌基因,如作为分子钟的 16S 核糖体 RNA 基因。将这些技术应用于 COPD 患者中,提示了微生物多样性,这些多样性因年龄、疾病严重程度和药物使用而有所不同。所有这些数据都为呼吸道微生物组在疾病发生和表达中的潜在作用提供了独特且快速发展的见解。

相似文献

1
Significance of the microbiome in chronic obstructive pulmonary disease.微生物组在慢性阻塞性肺疾病中的意义。
Ann Am Thorac Soc. 2013 Dec;10 Suppl(Suppl):S170-9. doi: 10.1513/AnnalsATS.201306-204AW.
8
The Sputum Microbiome in Chronic Obstructive Pulmonary Disease Exacerbations.慢性阻塞性肺疾病急性加重期的痰液微生物组
Ann Am Thorac Soc. 2015 Nov;12 Suppl 2(Suppl 2):S176-80. doi: 10.1513/AnnalsATS.201506-319AW.
9
COPD and the microbiome.慢性阻塞性肺疾病与微生物组。
Respirology. 2016 May;21(4):590-9. doi: 10.1111/resp.12732. Epub 2016 Jan 27.

引用本文的文献

6
Protein Biomarkers for COPD Outcomes.慢性阻塞性肺疾病结局的蛋白生物标志物。
Chest. 2021 Jun;159(6):2244-2253. doi: 10.1016/j.chest.2021.01.004. Epub 2021 Jan 9.
10
Exacerbation induces a microbiota shift in sputa of COPD patients.加重会引起 COPD 患者痰液中的微生物群落发生变化。
PLoS One. 2018 Mar 26;13(3):e0194355. doi: 10.1371/journal.pone.0194355. eCollection 2018.

本文引用的文献

4
Chronic bronchitis and chronic obstructive pulmonary disease.慢性支气管炎和慢性阻塞性肺疾病。
Am J Respir Crit Care Med. 2013 Feb 1;187(3):228-37. doi: 10.1164/rccm.201210-1843CI. Epub 2012 Nov 29.
8
The microbiome of the lung.肺部微生物组。
Transl Res. 2012 Oct;160(4):258-66. doi: 10.1016/j.trsl.2012.02.005. Epub 2012 Feb 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验